Q Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Q Therapeutics, Inc.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.
Allowing other stem cell companies to use the protocol honed by Neuralstem instead of starting at square one would speed promising therapies to ALS patients and advance the field, researchers and patient advocates argued at FDA’s hearing on ALS drug development and regulation.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- NeuroQ Research, Inc.
- Q Holdings, Inc.
- Q Therapeutic Products, Inc.